Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
MDxHealth ( (MDXH) ) has shared an update.
On January 12, 2026, MDxHealth reported preliminary, unaudited fourth-quarter 2025 revenue of about $30.5 million and full-year 2025 revenue of roughly $109 million, marking year-on-year growth of 23% and 21% respectively, with strong expansion in liquid-based testing volumes following the integration of the Exosome Diagnostics business and conversion of Select mdx customers to the ExoDx platform. The company ended 2025 with $29 million in cash and issued 2026 revenue guidance of $137–140 million, implying 26–28% growth, while also amending the earnout terms tied to its 2022 GPS acquisition by spreading remaining payments to Exact Sciences over 2026–2028 and granting warrants for 3 million shares, a move that aims to ease near-term cash obligations as MDxHealth pursues scale and improved profitability in a competitive diagnostics market.
The most recent analyst rating on (MDXH) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on MDxHealth stock, see the MDXH Stock Forecast page.
Spark’s Take on MDXH Stock
According to Spark, TipRanks’ AI Analyst, MDXH is a Neutral.
MDxHealth’s overall stock score is primarily influenced by its financial performance challenges, including negative equity and cash flow issues. While the earnings call provided some positive insights into revenue growth and strategic acquisitions, the technical analysis and valuation metrics indicate bearish sentiment and financial instability. The company’s efforts to improve profitability and strategic positioning are noted, but significant risks remain.
To see Spark’s full report on MDXH stock, click here.
More about MDxHealth
MDxHealth SA is a precision diagnostics company specializing in molecular tests that provide actionable genomic, epigenomic, exosomal and other molecular information to personalize diagnosis and treatment, primarily in prostate cancer and other urologic diseases. Its test menu, expanded through acquisitions such as Exosome Diagnostics and the GPS prostate cancer business, is marketed largely to urology practices, positioning the company within the high-growth segment of oncology-focused diagnostic testing.
Average Trading Volume: 187,855
Technical Sentiment Signal: Sell
Current Market Cap: $161.9M
Find detailed analytics on MDXH stock on TipRanks’ Stock Analysis page.